Trop-2 and Ephrin B2 expression in urothelial carcinoma with divergent differentiation and aggressive urothelial carcinoma subtypes
American Journal of Clinical Pathology · 2025
DOI: 10.1093/ajcp/aqae161 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Clinical Pathology, 2025. Verfasst von Katherine B Case und 11 weiteren Autor:innen. Beteiligte Einrichtung: Emory University School of Medicine, Atlanta, GA, US. Hauptthemen laut MEDLINE: Ephrin-B2, Antigens, Neoplasm, Cell Adhesion Molecules, Biomarkers, Tumor. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NCI, NIH HHS.
Abstract (Originalsprache)
Objectives
Urothelial carcinomas (UCs) encompass a heterogeneous group of tumors. Several histopathologic features are associated with poor clinical outcomes and limited treatment options. With new rising therapeutic modalities, we aimed to determine the pattern of expression of Trop-2 and ephrin B2 in UC with aggressive subtype histology and/or divergent differentiation (SH/DD).
Methods
We performed a retrospective analysis of 113 UC samples with SH/DD at our institution from 2011 to 2021. Immunohistochemical staining for Trop-2 and ephrin B2 expression was performed on all cases. Expression was determined by the percentage of samples with a moderate or strong H-score.
Results
Our results show Trop-2 expression was the highest in squamous cell carcinoma and UC with squamous differentiation, adenocarcinoma and UC with glandular differentiation, and plasmacytoid subtype, while ephrin B2 expression was highest in adenocarcinoma, UC with glandular differentiation, and small cell carcinoma.
Conclusions
Expression of Trop-2 and ephrin B2 may demonstrate therapeutic possibilities for patients with SH/DD, who usually have limited treatment options, particularly in small cell carcinoma, in which few targets have been identified. Clinical trials to investigate the efficacy of these novel treatments are warranted.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Emory University School of Medicine, Atlanta, GA, US.
- Department of Internal Medicine, Massachusetts General Hospital, Boston, MA, US.
- Department of Anatomic Pathology, University of Alabama at Birmingham, Birmingham, AL, US.
- Department of Pathology, Massachusetts General Hospital, Boston, MA, US.
- Department of Hematology and Oncology, Emory University School of Medicine, Atlanta, GA, US.
- Winship Cancer Institute of Emory University, Atlanta, GA, US.
ORCID-Profile: Bassel Nazha
Förderung
- NCI NIH HHS
- NCI
- NIH HHS
- NIH
Zitieren
APA
Case, K. B., Martini, D. J., Dababneh, M. N., Bidot, S., Nazha, B., Brown, J., Joshi, S., Narayan, V., Parihar, V., Saeed, F., Bilen, M. A., & Harik, L. R. (2025). Trop-2 and Ephrin B2 expression in urothelial carcinoma with divergent differentiation and aggressive urothelial carcinoma subtypes. American Journal of Clinical Pathology. https://doi.org/10.1093/ajcp/aqae161
Vancouver
Case KB, Martini DJ, Dababneh MN, Bidot S, Nazha B, Brown J, et al. Trop-2 and Ephrin B2 expression in urothelial carcinoma with divergent differentiation and aggressive urothelial carcinoma subtypes. American Journal of Clinical Pathology. 2025. doi:10.1093/ajcp/aqae161
BibTeX
@article{Case2025,
author = {Case, Katherine B and Martini, Dylan J and Dababneh, Melad N and Bidot, Samuel and Nazha, Bassel and Brown, Jacqueline and Joshi, Shreyas and Narayan, Vikram and Parihar, Vaunita and Saeed, Faisal and Bilen, Mehmet Asim and Harik, Lara R},
title = {Trop-2 and Ephrin B2 expression in urothelial carcinoma with divergent differentiation and aggressive urothelial carcinoma subtypes},
journal = {American Journal of Clinical Pathology},
year = {2025},
doi = {10.1093/ajcp/aqae161}
}
EUVIMED